AI Blood Test Interpretation for Laboratory Analyzers and POC Devices

How Aima Diagnostics adds a new layer of clinical intelligence and commercial value to diagnostic equipment — from new analyzers to devices already installed in healthcare facilities.

The next generation of laboratory diagnostics will be defined not only by how accurately equipment measures biomarkers, but also by how effectively those results can be interpreted and used in clinical practice.
Aima Diagnostics brings these capabilities together through AI-powered blood test interpretation technology designed for integration with laboratory analyzers, point-of-care testing (POCT) devices, and healthcare information systems.
By adding an intelligent interpretation layer to diagnostic equipment, Aima Diagnostics enables manufacturers to enhance their products, develop new digital services, and strengthen their competitive positioning. For laboratories and healthcare providers, the technology offers a more efficient way to turn laboratory measurements into structured, clinically meaningful information.
Importantly, AI integration is not limited to newly manufactured devices. Aima Diagnostics can support the connection of compatible analyzers already installed in medical institutions, extending their functionality without requiring replacement of the underlying hardware.
The company provides an end-to-end technology partnership covering equipment connectivity, software infrastructure, customization, implementation, maintenance, updates, and ongoing support.

The result is a new approach to laboratory diagnostics: combining trusted analytical equipment with an additional layer of AI-powered clinical intelligence.
1. AI Blood Test Interpretation: A New Value Layer for Diagnostic Equipment
Traditionally, the commercial value of laboratory equipment has been determined by analytical accuracy, testing speed, throughput, reliability, reagent availability, and cost per test.
These characteristics remain essential. However, as diagnostic technologies advance, manufacturers increasingly need additional ways to differentiate their products and deliver greater value to healthcare customers.
AI-powered interpretation introduces an entirely new dimension.
A laboratory analyzer measures biomarkers. Aima Diagnostics adds software intelligence designed to interpret the resulting data, identify meaningful relationships between laboratory parameters, evaluate available trends, and generate structured reports for healthcare professionals.
This creates three interconnected layers of value.
Analytical Value: Reliable Laboratory Measurements
The foundation remains the diagnostic instrument itself.
Clinical chemistry analyzers, hematology systems, immunoassay platforms, and POC devices provide the laboratory measurements essential to medical decision-making.
Instrument manufacturers continue to deliver value through analytical precision, reproducibility, performance, reliability, and testing capabilities.
Clinical Intelligence: Turning Results into Meaningful Insights
Aima Diagnostics adds an AI-powered interpretation layer to the measurement process.
Rather than presenting laboratory values only as isolated numbers, the technology is designed to analyze relationships between biomarkers, identify relevant patterns, evaluate available longitudinal data, and present findings in structured reports.
This additional analytical functionality supports clinicians in understanding complex laboratory information and incorporating it into clinical decision-making.
Commercial Value: Expanding the Product's Market Potential
AI functionality creates new opportunities for manufacturers to differentiate their equipment, introduce premium software capabilities, expand their product portfolios, and establish recurring digital revenue streams.
The product evolves from a standalone measurement device into a component of a broader intelligent diagnostic solution.

Aima Diagnostics enables manufacturers to compete on more than instrument performance — adding clinical intelligence, digital functionality, and long-term service value to their diagnostic technology.
2. How AI Integration Elevates Laboratory Equipment Positioning
For diagnostic equipment manufacturers, AI integration represents a strategic product development opportunity.
Instead of competing exclusively on technical specifications and pricing, manufacturers can offer an enhanced diagnostic experience built around the practical use of laboratory data.
From Standalone Analyzers to AI-Enabled Diagnostic Solutions
The traditional value proposition of a laboratory analyzer focuses on obtaining reliable measurements.
An AI-enabled diagnostic solution extends that proposition by combining measurement capabilities with automated interpretation, structured reporting, and integration into clinical workflows.
This strengthens the manufacturer's position as a provider of comprehensive diagnostic technology rather than equipment alone.

Stronger Competitive Differentiation
When competing instruments offer comparable analytical performance, additional digital functionality becomes an important product differentiator.
AI-powered interpretation gives manufacturers a compelling new feature to present during product demonstrations, procurement discussions, and commercial negotiations.
It also creates opportunities to develop distinct product configurations for customers with different digital and clinical requirements.

Premium Product Positioning
Intelligent software capabilities provide a foundation for higher-value product offerings.
Manufacturers can introduce enhanced configurations, premium digital packages, and advanced software services that extend beyond the instrument's core analytical functions.
This allows commercial discussions to focus on the complete value of the diagnostic solution rather than the purchase price of the device alone.

Recurring Digital Revenue
AI interpretation expands the range of monetization models available to equipment manufacturers.
Potential commercial structures include:

• AI interpretation subscriptions.
• Per-report processing fees.
• Enterprise software licensing.
• Premium digital service packages.
• OEM software licensing.
• White-label AI solutions.
• Integration and software maintenance contracts.

These models create opportunities to build ongoing customer relationships around software functionality and services.
Greater Value from the Existing Installed Base
One of the most significant opportunities is the ability to add AI functionality to compatible equipment that customers already own.
Rather than limiting advanced functionality to new instrument sales, manufacturers can introduce additional software services across their installed base.
This expands the commercial potential of equipment throughout its operational lifecycle.

Faster Access to Specialized Medical AI Technology
Developing medical AI requires specialized expertise in machine learning, laboratory medicine, clinical interpretation, software engineering, and medical data processing.
Aima Diagnostics provides a technology partnership model that allows manufacturers to integrate dedicated AI interpretation capabilities into their diagnostic solutions without building every component independently.

The strategic opportunity is clear: manufacturers can increase product value, enhance differentiation, and expand their digital business models while continuing to focus on their core expertise in diagnostic instrumentation.

3. AI Integration for Point-of-Care Testing (POCT) Analyzers
Point-of-care testing is one of the most promising applications for AI-powered laboratory interpretation.
POC analyzers provide diagnostic results directly at or near the location of patient care, including hospitals, emergency departments, outpatient clinics, physician offices, and decentralized healthcare facilities.
These systems play an important role in making laboratory information available quickly.
Aima Diagnostics adds another layer to that process: structured AI interpretation of the available results.
AI Interpretation of Cardiac Biomarkers
Depending on the analyzer, POC devices may measure biomarkers such as:

• Cardiac troponin I (cTnI).
• NT-proBNP.
• Myoglobin.

Aima Diagnostics can be integrated into workflows that organize and interpret these laboratory results in conjunction with other available information.
For example, AI-assisted reporting can help present biomarker values, available trends, and clinically relevant relationships in a structured format.
This gives healthcare professionals an additional analytical resource when reviewing laboratory findings.
AI Interpretation of Inflammation and Infection Biomarkers
POC analyzers may also measure:

• C-reactive protein (CRP).
• High-sensitivity C-reactive protein (hs-CRP).
• Procalcitonin (PCT).
• Serum amyloid A (SAA).

These markers provide important information in a range of clinical situations.
AI interpretation can support the combined assessment of available results and provide structured information for clinicians evaluating inflammatory processes.
Hemostasis and Additional Biomarkers
Other applications include laboratory parameters such as D-dimer, glucose, electrolytes, and additional supported diagnostic markers.
As the number of available POC assays continues to expand, intelligent interpretation becomes an increasingly relevant addition to point-of-care workflows.
Why AI Matters for POC Equipment Manufacturers
POC manufacturers already compete on speed, portability, analytical quality, usability, and the breadth of their testing menus.

Aima Diagnostics introduces an additional competitive dimension: the ability to provide meaningful analytical information alongside rapid laboratory measurements.
This strengthens the overall product proposition and expands the possibilities for software-enabled diagnostic services.

4. AI Integration with New and Existing Laboratory Analyzers
Aima Diagnostics is designed around a fundamental principle: healthcare institutions should be able to benefit from modern AI technology while preserving their existing investments in diagnostic infrastructure.
The integration approach supports two primary deployment scenarios.
AI Integration with New Laboratory Equipment
Equipment manufacturers can incorporate AI interpretation into new diagnostic systems, enhanced product configurations, or integrated software packages.
Depending on the product architecture, Aima Diagnostics can be connected through APIs, middleware, laboratory information systems, or dedicated integration components.
This provides a foundation for integrated AI-enabled equipment offerings and OEM partnerships.
Upgrading Existing Laboratory Equipment with AI
Many hospitals, clinics, and laboratories already operate reliable analyzers that meet their analytical requirements.
Replacing these devices solely to introduce new software capabilities would create unnecessary capital expenditure.
Aima Diagnostics addresses this opportunity by enabling AI connectivity with compatible installed analyzers through their available data interfaces or existing laboratory information infrastructure.
Potential equipment categories include:

• Clinical chemistry analyzers.
• Hematology analyzers.
• Immunoassay and immunochemistry systems.
• Point-of-care analyzers.
• Automated laboratory platforms.
• Other systems producing compatible structured laboratory results.

The integration architecture is designed to accommodate a broad range of analyzer types and configurations. Compatibility is evaluated according to each device's manufacturer, model, communication protocols, and available data interfaces.
Equipment already connected to a laboratory information system can often be evaluated for AI integration through that existing infrastructure, reducing the need for changes at the instrument level.
Existing diagnostic hardware can gain an additional layer of AI interpretation, extending its functional and commercial value without requiring changes to its core measurement technology.
This approach is particularly valuable for healthcare groups operating substantial installed equipment fleets or multiple analyzer brands.

5. LIS AI Integration: Connecting Laboratory Data with Clinical Intelligence
Laboratory Information Systems (LIS) play a central role in modern diagnostic workflows.
They connect analyzers, manage laboratory data, organize test results, and support communication between laboratories and healthcare providers.
Integrating AI at the LIS level creates an efficient way to extend intelligent interpretation across multiple laboratory instruments.
How LIS AI Integration Works
Laboratory results are transmitted from connected analyzers to the existing LIS or integration middleware.
Through an agreed interface, the relevant data can then be transferred securely to Aima Diagnostics for AI-powered interpretation.
The resulting report can be delivered to an authorized clinical interface, laboratory system, electronic health record, or other approved destination.
Depending on the infrastructure, integration can use:

• REST APIs.
• JSON data structures.
• HL7 messaging.
• HL7 FHIR resources.
• Laboratory middleware.
• Dedicated integration gateways.

This architecture enables AI functionality to operate across multiple compatible analyzers without requiring an independent AI connection for every instrument.
Integration with EHR, HIS, and LIMS Platforms
Aima Diagnostics can also be incorporated into broader healthcare information workflows involving:
Electronic Health Records (EHR): Presenting laboratory interpretation alongside other patient information.
Hospital Information Systems (HIS): Supporting integration with institutional clinical workflows.
Laboratory Information Management Systems (LIMS): Connecting AI interpretation with laboratory data management processes.
Clinical reporting platforms: Delivering structured findings to healthcare professionals through existing interfaces.
The objective is to make AI interpretation accessible within familiar workflows rather than introducing unnecessary parallel systems.
Benefits for Laboratory Networks
For networks operating multiple laboratories or clinical locations, centralized AI integration creates opportunities to standardize report presentation, manage software services, and expand intelligent functionality across compatible systems.
A single integration strategy can support a broader digital transformation program spanning multiple sites and equipment manufacturers.
Technical Compatibility Assessment: Target Turnaround of 5 Business Days
Manufacturers and healthcare institutions can begin by submitting basic technical information about their analyzers and existing software infrastructure.
Aima Diagnostics targets an initial technical compatibility assessment within 5 business days after receiving the information required for review.
The assessment focuses on the analyzer's connectivity options, supported laboratory parameters, available data formats, and potential integration architecture.
The outcome provides a practical starting point for defining the appropriate connection method and the next steps toward technical testing.
This approach allows prospective partners to explore AI integration without committing to a large-scale infrastructure project at the outset.
6. End-to-End AI Integration, Deployment, and Support
Aima Diagnostics offers more than AI interpretation technology.
The company provides a comprehensive implementation approach designed to address the practical requirements of manufacturers, laboratories, and healthcare institutions throughout the technology lifecycle.
This covers the process from initial infrastructure assessment to ongoing software support and functional development.
Step 1. Technical Infrastructure Assessment
The process begins with an evaluation of the organization's existing diagnostic equipment and information systems.
The assessment covers analyzer models, communication interfaces, testing menus, laboratory information systems, data formats, expected processing volumes, and technical requirements.
This establishes the integration architecture and identifies the most effective way to connect existing systems.
Step 2. Equipment Connectivity and System Integration
Aima Diagnostics coordinates the connection of compatible diagnostic equipment and the configuration of required data exchange mechanisms.
Integration can be implemented through direct APIs, laboratory middleware, existing LIS interfaces, or dedicated software connectors.
The architecture is designed to support reliable communication between laboratory equipment and the AI interpretation platform.
Step 3. Custom Software Configuration
Every healthcare institution has different requirements.
Aima Diagnostics provides software configuration tailored to each organization's agreed technical and operational needs.
This can include:

• Laboratory test and biomarker mapping.
• Measurement unit standardization.
• Reference interval configuration.
• Assay-specific data handling.
• AI report formatting.
• Language localization.
• User roles and permissions.
• Workflow configuration.
• Report delivery settings.
• Integration with existing clinical interfaces.

The objective is to make the AI functionality work naturally within the institution's diagnostic environment.
Step 4. Software and Computing Infrastructure
Aima Diagnostics coordinates the software environment required for laboratory data processing, AI interpretation, report generation, and system connectivity.
Depending on project requirements, the architecture can be designed around supported cloud-based, on-premises, or hybrid infrastructure.
The technical solution may incorporate secure data transmission, authentication, access control, integration monitoring, processing services, and reporting components.
This allows healthcare customers to obtain an integrated technology solution rather than assemble and maintain independent software components themselves.
Step 5. Testing and Quality Assurance
Before operational deployment, the integrated system undergoes technical testing.
Key areas include data consistency, test identifier mapping, unit handling, successful report generation, transmission reliability, and error handling.
The deployment process also incorporates the appropriate verification and clinical evaluation activities for the intended application.
Step 6. Staff Training and Workflow Adoption
Aima Diagnostics supports the adoption of the technology by helping participating organizations establish appropriate user workflows.
Training can cover system operation, AI report review, source data verification, user access, and technical support procedures.
The focus is on integrating AI into routine work with minimal disruption to established processes.
Step 7. Technical Maintenance and Operational Support
Aima Diagnostics provides for ongoing software maintenance and support within the agreed service arrangement.
Support can cover:

• Monitoring system connectivity.
• Troubleshooting integration issues.
• Maintaining software components.
• Managing software versions.
• Supporting interface changes.
• Monitoring processing performance.
• Managing technical incidents.
• Coordinating security updates.
• Supporting backup and recovery procedures.
• Providing technical assistance to institutional IT teams.

Service responsibilities and performance commitments are established through the relevant support agreement and Service Level Agreement (SLA).
Step 8. Continuous Updates and Scalability
As healthcare organizations expand, their technology requirements change.
Additional analyzers may be introduced, new laboratory sites opened, testing menus expanded, and information systems upgraded.

Aima Diagnostics provides a framework for extending the integration, maintaining compatibility, updating supported software functionality, and scaling across additional devices and locations.
The result is a long-term technology partnership that covers the entire AI integration lifecycle — connectivity, configuration, deployment, maintenance, upgrades, and expansion.
Typical Technical Pilot: 1–4 Weeks
A focused technical integration pilot can be planned for approximately 1–4 weeks, depending on equipment compatibility, data availability, interface readiness, and the agreed scope of work.
The pilot begins after technical requirements have been established and the necessary data, documentation, and system access have been provided.
The objective is to demonstrate a complete working integration, including:

• Receiving laboratory results from the analyzer or information system.
• Transferring data to the AI platform.
• Processing supported biomarkers.
• Generating a structured AI interpretation report.
• Returning the report through the agreed delivery interface.
• Evaluating technical performance and workflow compatibility.

This timeframe concerns the technical integration pilot. Any separate clinical evaluation, regulatory authorization, or production rollout follows its own project requirements.
A structured pilot provides manufacturers and healthcare organizations with a practical way to evaluate AI integration before expanding it across additional devices or facilities.
7. Benefits for Diagnostic Equipment Distributors and Suppliers
For distributors and medical technology suppliers, AI interpretation provides an opportunity to move beyond traditional equipment sales.
Instead of competing primarily on instrument price, reagent costs, and technical specifications, distributors can offer a broader diagnostic solution combining hardware, software intelligence, and technology services.
A More Valuable Commercial Offering
AI-enhanced laboratory equipment gives distributors an additional product capability to present to healthcare customers.
The conversation moves beyond what an analyzer measures to how the complete diagnostic solution supports clinical workflows and laboratory operations.
Differentiation in Competitive Markets
Distributors can position AI-enabled solutions as technologically advanced offerings that combine reliable laboratory measurements with intelligent reporting capabilities.
This creates additional commercial arguments when competing for customers, procurement agreements, and long-term equipment supply relationships.
New Opportunities with Existing Customers
Installed equipment represents an established customer relationship.
Where compatibility permits, distributors can introduce AI interpretation as an additional service for customers who already own supported analyzers.
This expands the opportunity for commercial engagement beyond the initial equipment sale.
Recurring Software and Service Revenue
Under appropriate commercial agreements, distributors can participate in the delivery, promotion, implementation, or support of AI-enabled services.
This creates opportunities to supplement equipment and consumables sales with digital services.
8. Benefits for Medical Laboratories and Clinics
For healthcare institutions, the value of AI interpretation extends across clinical workflows, technical infrastructure, and operational efficiency.
More Efficient Laboratory Result Review
Clinicians frequently need to review numerous laboratory values, identify abnormalities, compare related parameters, and examine historical results.
Aima Diagnostics helps organize this information into structured analytical reports, reducing the need to manually assemble and review disconnected data.
This creates opportunities to streamline initial result assessment and make complex laboratory information easier to navigate.
Better-Informed Clinical Decisions
A single laboratory value rarely tells the complete clinical story.
The relationship between different biomarkers, their changes over time, and the available patient context can provide important additional information.
Aima Diagnostics is designed to bring these elements together and present relevant findings in a structured format that supports professional clinical judgment.
Greater Value from Existing Equipment
AI interpretation can be introduced through compatible analyzers and existing information systems, allowing healthcare institutions to expand digital capabilities while maintaining their current hardware investments.
Reduced Internal Integration Burden
The comprehensive deployment model allows clinics and laboratories to coordinate connectivity, software configuration, technical support, and updates through an established technology partnership.
This reduces the need to build every integration component or AI capability internally.
Consistent Reporting Across Laboratory Systems
For healthcare organizations operating different analyzers or multiple laboratory departments, a unified AI reporting approach can improve the consistency and accessibility of analytical information.
This is especially relevant for institutions seeking standardized digital workflows across departments and locations.
9. Benefits for Clinicians: More Insight, Less Manual Data Processing
The value of medical AI is not defined by the number of conclusions it generates, but by the usefulness of the information it provides.
Aima Diagnostics is designed to assist clinicians in working with complex laboratory data through structured interpretation and analytical reporting.
Its approach supports:

• Faster navigation through extensive laboratory panels.
• Identification of significant biomarker relationships.
• Review of available changes over time.
• More structured presentation of laboratory abnormalities.
• Easier access to relevant analytical information.
• More efficient preparation for clinical review.

By organizing laboratory information into a coherent report, AI can help clinicians spend less effort assembling data and more attention evaluating the patient's overall clinical situation.
The objective is to make laboratory data easier to interpret and use while keeping medical expertise and clinical judgment at the center of patient care.
10. Scalable AI Infrastructure for Multi-Site Laboratory Networks
Large diagnostic networks may operate dozens or hundreds of analyzers across multiple facilities.
These systems often come from different manufacturers and use different data interfaces, laboratory information systems, and operational processes.
Aima Diagnostics provides an integration-oriented approach that supports the development of a unified AI interpretation infrastructure across compatible systems.
This creates opportunities for centralized administration, consistent reporting, coordinated software updates, and the gradual expansion of AI functionality across a network.
A healthcare organization can begin with a selected laboratory or analyzer group and extend the integration to additional facilities.
This approach supports a scalable digital infrastructure without requiring an immediate replacement of existing diagnostic systems.
For large laboratory networks, AI becomes an enterprise-level capability rather than a feature limited to individual instruments.
11. From Technical Assessment to AI Integration Pilot
Aima Diagnostics follows a structured approach to evaluating and implementing new equipment integrations.
Phase 1: Compatibility Assessment
The manufacturer or healthcare institution provides information about the equipment, supported laboratory tests, available communication interfaces, and existing IT infrastructure.
Aima Diagnostics evaluates the technical integration requirements and identifies the appropriate connectivity architecture.
Target timeframe: within 5 business days of receiving the required technical information.
Phase 2: Integration Design
The parties define the data exchange process, supported biomarkers, software components, report delivery workflow, and project responsibilities.
Phase 3: Technical Pilot
A selected analyzer or laboratory system is connected to demonstrate the complete workflow from laboratory result generation to AI interpretation and report delivery.
Typical target duration: 1–4 weeks following technical readiness and project kickoff.
Phase 4: Evaluation
The integration is assessed against agreed technical and, where relevant, clinical performance criteria.
Key technical indicators can include:

• Data transmission success rate.
• Correct mapping of laboratory parameters.
• Report generation reliability.
• Processing latency.
• Integration stability.
• User workflow compatibility.

Clinical evaluation criteria are defined according to the intended medical application.
Phase 5: Deployment and Expansion
Following successful evaluation and completion of the applicable requirements, the integration can be extended to additional analyzers, facilities, or product lines.
This creates a practical path from a focused technical project to a broader commercial partnership.
12. Commercial Opportunities: OEM, White-Label, and AI Licensing
Aima Diagnostics supports the development of technology partnerships aligned with different equipment manufacturers' commercial strategies.
OEM Integration
Manufacturers can incorporate AI interpretation into their broader diagnostic solutions through a negotiated OEM technology arrangement.
This allows AI functionality to complement the manufacturer's existing product architecture and commercial offering.
White-Label Solutions
A white-label arrangement can allow manufacturers or technology partners to offer agreed AI-enabled capabilities within their own branded software environment.
This supports a unified customer experience and consistent product positioning.
AI Interpretation as a Service
Manufacturers and healthcare providers can explore subscription-based or usage-based models for AI-generated laboratory reports.
This provides a commercial framework for recurring digital services.
Enterprise Licensing
Laboratory networks and healthcare organizations operating multiple facilities can explore enterprise licensing models designed around their infrastructure and expected usage.
Joint Product Development
Aima Diagnostics can work with technology partners on integration design, workflow adaptation, and the development of additional AI-enabled diagnostic capabilities.
These models give manufacturers and healthcare providers the flexibility to integrate AI technology into their existing product and business strategies.
13. Technology, Clinical Quality, and Regulatory Considerations
AI-powered laboratory interpretation operates at the intersection of medical technology, software engineering, and clinical decision support.
A successful implementation requires reliable laboratory data, clear traceability, appropriate security measures, and defined responsibilities for software operation.
Clinical evaluation and regulatory requirements are determined by the system's intended use, functionality, and target market. Depending on the application, medical software may fall within the scope of EU MDR or IVDR requirements or applicable FDA oversight in the United States.
AI-generated interpretations are intended to support qualified healthcare professionals and do not replace independent medical assessment, diagnosis, or treatment decisions.
These principles provide the foundation for responsible deployment and long-term adoption in clinical environments.
14. The Future of Laboratory Diagnostics: From Measurement to Intelligence
Laboratory equipment has become increasingly accurate, automated, and accessible.
The next stage of innovation is to make the resulting medical data more useful.
AI-powered interpretation brings a new dimension to traditional laboratory diagnostics by connecting analytical measurements with intelligent data processing and structured clinical information.
For manufacturers, this represents an opportunity to elevate product positioning, expand digital functionality, strengthen competitive differentiation, and develop new software-based revenue models.
For distributors, it creates more comprehensive commercial offerings and additional opportunities within existing customer relationships.
For laboratories and clinics, it offers a way to enhance existing infrastructure and streamline laboratory data workflows.
For clinicians, it provides additional analytical support when reviewing complex laboratory results.
Aima Diagnostics is building the AI interpretation layer that connects laboratory equipment with the next generation of intelligent diagnostic services.
Through an end-to-end approach covering technical integration, software infrastructure, customization, maintenance, and continuous development, the company helps manufacturers and healthcare institutions bring AI interpretation into practical diagnostic workflows.
The central opportunity is to extend the value of laboratory equipment beyond measurement alone — making it part of a broader digital diagnostic ecosystem.

Bring AI-Powered Interpretation to Your Laboratory EquipmentRequest an AI Connection or Testing Pilot
Already manufacturing diagnostic analyzers or operating laboratory equipment? Discover how Aima Diagnostics can add an intelligent interpretation layer to your existing technology.